Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Innavirvax (France), a biopharmaceutical company focused on therapeutic solutions of pathologies associated with immune deregulation, closed a $4.9M Series B financing. Participants include Pradeyrol Développement, Fa Dièse, CapDecisif Management and FRCI.

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.

Cytheris (France) a clinical-stage biopharmaceutical immune modulation company focused on HIV, HCV and oncology, closed a $14.3M Series D financing. Participants include CDC Entreprises, Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity and Forbion Capital Partners.

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.

Argos Therapeutics (Research Triangle Park, NC) clinical-stage developer of personalized immunotherapies for cancer and HIV, closed a $35.2M Series C financing. Participants include TVM Capital, Mizuho Capital, Morningside Group, Japan Asia Investment Group, Lumira Capital, Forbion Capital Partners, CDP Capital, Intersouth Partners, Aurora Capital and GeneChem.

Concert Pharmaceuticals (Lexington, MA) development-stage pharmaceutical company focused on new chemical entities based upon modifications of validated drug molecules using deuterium chemistry, closed a $37M Series C financing. Participants include Adage Capital Management, SR One, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, Flagship Ventures, Greylock […]

  Sequoia Pharmaceuticals (Gaithersburg, MD) drug developer focused on the treatment of drug-resistant HIV infections, has raised $35M in Series C funding. The deal was led by Wellcome Trust and existing investors Healthcare Ventures, Sofinnova Partners and Aberdare Ventures. The round was also joined by MedImmune Ventures.

VIRxSYS Corporation (Gaithersburg, MD), who is developing genetic therapies for HIV and cancer, closed a $20M Series G round of financing, the company has raised a total of $87M to date. The financing will be used to support research and clinical programs including VRX496, a gene-based immunotherapy for the treatment of HIV. Phase II clinical […]


to top of page...